HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lowe-Ponsford, F. Articles by Baldwin, D. Search for Related Content PubMed Articles by Lowe-Ponsford, F. Articles by Baldwin, D.

Off-label prescribing by psychiatrists

Bay Tree House, Graham Road, Southampton, Hants S014 0YH

David Baldwin, Senior Lecturer and Honorary Consultant Psychiatrist

Southampton University Mental Health Group, Royal South Hampshire Hospital, Brinton's Terrace, Southampton, Hants S014 0YG

	Abstract

Top Abstract Introduction Method Results Discussion References

 
A questionnaire was sent to 200 psychiatrists asking them about their off-label prescribing in the preceding month. One hundred and sixteen replies (58%) were obtained. Seventy-six (65%) respondents had prescribed medication off-label within the past month. Only 5 (4%) had ever received a complaint from patients related to their off-label prescribing. If this region is typical, off-label prescribing is common amongst psychiatrists. No formal guidelines exist except for the use of high dose neuroleptics. A suggested guideline is given in this article.

	Introduction

Top Abstract Introduction Method Results Discussion References

 
Many psychiatrists think that off-label prescribing is occasionally necessary when attempting to treat the very ill or treatment-resistant patient. However, the prevalence of this practice among psychiatrists is not known. In their summary of the development of product licences, Healy and Nutt (1998) perceived need for licences to state the indications for their drugs and also for the pharmaceutical companies to provide proof of efficacy for stated indications. They also describe the barriers to obtaining a product licence: these include the need for the company to make an economic return balanced against the high cost of clinical trials. Some clinical trials are very difficult to perform (eg. for the prophylaxis of bipolar disorder), or raise particular ethical difficulties (such as entering children or people with learning disabilities into studies). The authors concluded that use of off-label medication was a "necessary part of the art of medicine".

The use of off-label prescriptions has particularly exercised child and adolescent psychiatrists (since relatively few psychotropic drugs are licensed for use in children) and psychiatrists dealing with those with a learning disability (British Association for Psychopharmacology, 1997; Vitello & Jensen, 1997). A recently published study (Conroy et al, 2000) looked prospectively at off-label prescribing in five paediatric wards in five countries over a period of 4 weeks. In that study the term off-label prescribing included: changed frequency of prescribing, a different route of administration, modification of licensed drugs and prescribing important drugs. During the period of the study 67% of children were prescribed drugs off-label and 46% of all drug prescriptions were off-label.

Our survey was designed to see how common off-label prescribing is among psychiatrists and to ascertain whether it is felt that there are insufficient guidelines for this aspect of prescribing.

	Method

Top Abstract Introduction Method Results Discussion References

 
All senior psychiatrists (consultants, specialist registrars and non-career grades) working in the Wessex region were surveyed using a postal questionnaire. This was sent to each doctor twice, and an addressed return envelope was enclosed.

The questionnaire was anonymous, but sought brief details about the doctor's grade and speciality. It then asked questions in turn about each of the following three types of off-label prescribing:

1. prescribing for a drug outside its produce licence indication; an example would be the use of sodium valproate as a mood stabiliser (in the UK);
   
2. prescribing a drug above the maximum dose given in the data sheet;
   
3. prescribing a drug to a patient outside the recommended age range; an example would be the prescription of many of the new antidepressants in children.
   

The psychiatrist was asked if he or she had prescribed any drug off-label in the past month and to list any such drugs and their indications (or dosages, or age range, as appropriate). Questions were then asked about the legal status of the patients, whether the doctor had any worries about this aspect of prescribing and if they felt sufficient guidelines existed. The final section asked if the doctor had received any complaints from patients about their off-label prescribing; and also left space for comments. The name, use or dose of each drug given was checked with the ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1999-2000 (Association of the British Pharmaceutical Industry, 1999).

For ease of analysing results and to ensure anonymity all psychiatrists working predominantly with adults under the age of 65 years (eg. forensic psychiatrists, substance misuse specialists and psychotherapists) were included under the term ‘adult psychiatrists’. For similar reasons all non-career-grade doctors were included under a single grade. All percentages quoted were rounded to the nearest whole figure.

	Results

Top Abstract Introduction Method Results Discussion References

 
The response rate was 58%. Of the 116 who responded to the questionnaire, 65 (56%) were consultants, 33 (29%) were specialist registrars and 17 (15%) were noncareer grades; the response to grade was missing in one case. Thirteen (11%) respondents were working in child and adolescent psychiatry, 29 (25%) in old age psychiatry and 73 (63%) in adult specialities; again, 1 response was missing.

A total of 76 (65%) of the 116 respondents had prescribed drugs off-label in at least one of the three ways listed in the preceding month (Table 1).

Prescribing out of the product licence indication was carried out predominantly by adult and old age psychiatrists. As expected, there was little prescribing of drugs above the maximum recommended dosage.

Very few psychiatrists (n=5, 4%) had received complaints about their prescription of drugs off-label, but it was clear from comments that possible medico-legal problems were of concern to some respondents.

It was not possible to quantify the use of particular drugs, as the number of named drugs was often less than the total number of drugs given. This is probably because a particular drug was prescribed on more than one occasion. Examples of the drugs given included sodium valproate for bipolar disorder, olanzapine for psychoses other than schizophrenia, atypical antipsychotics for agitated dementia, reboxetine to the elderly and newer antidepressants to children.

There were insufficient replies to analyse the legal status of the patients given off-label drugs. However, responses indicated that the majority of patients were not detained under a section of the Mental Health Act, and of those who were, not all were able to consent.

	Discussion

Top Abstract Introduction Method Results Discussion References

 
The indications for drugs vary widely, even within the same class of compounds, and it is impractical for a practising psychiatrist to memorise them all for each drug. Examples of the variety of indications for seemingly similar drugs are given in Table 2. Owing to these variations it is possible that psychiatrists missed some reporting of their use of drugs off-label. Drugs that psychiatrists mistakenly thought that they had used off-label when in fact they had not were excluded from analysis.

As this is a retrospective survey, it is possible that psychiatrists may have forgotten all the drugs they had prescribed in the past month. It may have been better to have asked them to estimate their use prospectively over a longer period in order to obtain more definitive results, but this was not done as we did not believe it would be realistic for a busy doctor to complete such a task.

The reported use of high-dose neuroleptics may have been lower than the true figure. This is partly because of the effects of p.r.n. (as required) prescribing, which is not always taken into account when calculating neuroleptic dose (Milton et al, 1998). In addition, if a combination of neuroleptics is used at a combined dosage above British National Formulary (British Medical Association, 1999) recommendations, the figure may be even higher. Guidelines to the use of high dose neuroleptics have been published (Thompson, 1994).

The prescription of drugs out of age-range is potentially troublesome for the doctor. It is well known that psychiatrists dealing with children and adolescents may resort to off-label prescribing, as there are often no suitable treatment alternatives. Some drugs are not licensed for use in the elderly (eg. reboxetine) and this also can cause difficulties.

We felt that off-label prescribing is justified in certain circumstances. There is often good evidence for the use of drugs off-label (such as the use of sodium valproate in mania or olanzapine in psychoses other than schizophrenia). The newer antipsychotic drugs tend to be licensed for fewer indications (see Table 2), but they are thought by many to have a more acceptable side-effect profile for the patient. Some respondents cited fear of litigations as a reason for not prescribing drugs off-label, but the Bolam test in medical negligence claims (1957) asks for proof that a body of doctors would act similarly to the doctor in question. This would be easy to prove in many circumstances, for example many anticonvulsants are widely used in the UK and USA as a treatment of bipolar disorder, and many old age psychiatrists use low doses of antipsychotic drugs to reduce agitation in patients with dementia. The more recent Bolitho case (1997) also states that the medical opinion should be capable of withstanding logical analysis. Table 3 shows a suggested guide to prescribing off-label, which might help avoid potential difficulties. Particularly in view of the continuing emphasis on clinical governance and increased accountability, psychiatrists need to be able to defend their actions to both colleagues and patients.

	Acknowledgments

 
Thank you to Karen Middleton for technical assistance.

	References

Top Abstract Introduction Method Results Discussion References

 
ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY (1999) ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1999-2000. London: Datapharm Publications Limited.

BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY (1997) BAP consensus statement. Child and learning disability psychopharmacology. Journal of Psychopharmacology, 11, 291-294.[Abstract/Free Full Text]

BRITISH MEDICAL ASSOCIATION & ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN (1999) British National Formulary. London: Wallingford: BMJ Books. Pharmaceutical Press.

CONROY, S., CHOONARE, I., IMPICCIATORE, P., et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. British Medical Journal, 320, 79-82.[Abstract/Free Full Text]

HEALY, D. & NUTT, D. (1998) Prescriptions, licences and evidence. Psychiatric Bulletin, 22, 680-684.[Abstract/Free Full Text]

LOWE-PONSFORD, F. L. (1999) Anticonvulsants in the treatment of bipolar disorder. In Practical Issues in Mood and Anxiety Disorders. No. 8. The Netherlands: Smithkline Beecham.

MILTON, J., LAWTON, J., SMITH, M., et al (1998) Hidden high-dose antipsychotic prescribing: effects of p.r.n. doses. Psychiatric Bulletin, 22, 675-677.

THOMPSON, C. (for the Royal College of Psychiatrists' Panel) (1994) The use of high-dose antipsychotic medication (Consensus statement). British Journal of Psychiatry, 164, 448-458.[Free Full Text]

VITELLO, B. & JENSEN, P. S. (1997) Medication development and testing in children and adolescents. Archives of General Psychiatry, 54, 871-876.[Abstract]

Bolam v. Friern Hospital Management Committee [1957] WLR, 582.

Bolitho v. City and Hackney Health Authority [1997] 3WLR, 1151.

This article has been cited by other articles:

				D. S. Baldwin and N. Kosky Off-label prescribing in psychiatric practice Advan. Psychiatr. Treat., November 1, 2007; 13(6): 414 - 422. [Abstract] [Full Text] [PDF]

				C. Haw and J. Stubbs Benzodiazepines a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital J Psychopharmacol, August 1, 2007; 21(6): 645 - 649. [Abstract] [PDF]

				R. Hodgson and R. Belgamwar Off-label prescribing by psychiatrists Psychiatr. Bull., February 1, 2006; 30(2): 55 - 57. [Abstract] [Full Text] [PDF]

				D. Layton, S. Harris, L. V. Wilton, and S. A. W. Shakir Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia J Psychopharmacol, September 1, 2005; 19(5): 473 - 482. [Abstract] [PDF]

				C. Haw and J. Stubbs A survey of the off-label use of mood stabilizers in a large psychiatric hospital J Psychopharmacol, July 1, 2005; 19(4): 402 - 407. [Abstract] [PDF]

				J. Johnson and A. F. Clark Prescribing of unlicensed medicines or licensed medicines for unlicensed applications in child and adolescent psychiatry Psychiatr. Bull., December 1, 2001; 25(12): 465 - 466. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lowe-Ponsford, F. Articles by Baldwin, D. Search for Related Content PubMed Articles by Lowe-Ponsford, F. Articles by Baldwin, D.